NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
Clinical Trials
11 trialsNCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT04629729 2025-12-11
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT05712278 2025-09-12
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Sanofi
Phase 1 Terminated
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT04613557 2023-08-31
IMMUNICY-1
Celyad Oncology SA
Phase 1 Active not recruiting
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT04167696 2020-06-09
CYCLE-1
Celyad Oncology SA
Phase 1 Recruiting
NCT01701323 2019-03-01
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Terminated
NCT01310179 2015-06-10
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
PNP Therapeutics, Inc.
Phase 1 Completed